Salix Pharmaceuticals Ltd (SLXP) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Join SI Premium – FREE
Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q3 EPS of $0.77, $0.14 better than the analyst estimate of $0.63. Revenue for the quarter came in at $146.2 million versus the consensus estimate of $140.56 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
- Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
